CYPH
Price
$2.27
Change
+$0.07 (+3.18%)
Updated
Sep 11 closing price
Capitalization
244.09M
Intraday BUY SELL Signals
SABS
Price
$3.41
Change
-$0.01 (-0.29%)
Updated
Sep 11 closing price
Capitalization
309.35M
66 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYPH vs SABS

CYPH vs SABS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CYPH vs. SABS commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYPH is a Hold and SABS is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SABS($309M) has a higher market cap than CYPH($244M). SABS has higher P/E ratio than CYPH: SABS (14.17) vs CYPH (3.54). CYPH YTD gains are higher at: 95.259 vs. SABS (-8.824). CYPH has higher annual earnings (EBITDA): 1.26M vs. SABS (-9.43M). SABS has more cash in the bank: 103M vs. CYPH (7.62M). CYPH has less debt than SABS: CYPH (38K) vs SABS (5.13M). CYPH (0) and SABS (0) have equivalent revenues.
CYPHSABSCYPH / SABS
Capitalization244M309M79%
EBITDA1.26M-9.43M-13%
Gain YTD95.259-8.824-1,080%
P/E Ratio3.5414.1725%
Revenue00-
Total Cash7.62M103M7%
Total Debt38K5.13M1%
FUNDAMENTALS RATINGS
CYPH: Fundamental Ratings
CYPH
OUTLOOK RATING
1..100
34
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
PROFIT vs RISK RATING
1..100
89
SMR RATING
1..100
91
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
10

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYPHSABS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
89%
Bullish Trend 17 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 5 days ago
90%
COMPARISON
Comparison
Sep 13, 2026
Stock price -- (CYPH: $2.27 vs. SABS: $3.41)
Brand notoriety: CYPH and SABS are both not notable
CYPH represents the Investment Managers, while SABS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYPH: 185% vs. SABS: 267%
Market capitalization -- CYPH: $244.09M vs. SABS: $309.35M
CYPH [@Investment Managers] is valued at $244.09M. SABS’s [@Biotechnology] market capitalization is $309.35M. The market cap for tickers in the [@Investment Managers] industry ranges from $57 to $167.2B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Investment Managers] industry is $9.12B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYPH’s FA Score shows that 0 FA rating(s) are green while SABS’s FA Score has 0 green FA rating(s).

  • CYPH’s FA Score: 0 green, 5 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, CYPH is a better buy in the long-term than SABS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYPH’s TA Score shows that 5 TA indicator(s) are bullish while SABS’s TA Score has 4 bullish TA indicator(s).

  • CYPH’s TA Score: 5 bullish, 4 bearish.
  • SABS’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CYPH is a better buy in the short-term than SABS.

Price Growth

CYPH (@Investment Managers) experienced а -6.40% price change this week, while SABS (@Biotechnology) price change was -8.33% for the same time period.

The average weekly price growth across all stocks in the @Investment Managers industry was -3.01%. For the same industry, the average monthly price growth was +2.25%, and the average quarterly price growth was +9.49%.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

SABS is expected to report earnings on Nov 17, 2026.

Industries' Descriptions

@Investment Managers (-3.01% weekly)

Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CYPH
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BKRDX8.590.03
+0.35%
iShares Developed Real Estate Idx K
SDFSX21.25N/A
N/A
Sit Small Cap Dividend Growth S
DPWRX67.18N/A
N/A
BNY Mellon Worldwide Growth I
OSCCX22.24N/A
N/A
Invesco Main Street Small Cap C
STEZX19.32N/A
N/A
AB International Strat Eqs Z

CYPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYPH has been loosely correlated with INKT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYPH jumps, then INKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYPH
1D Price
Change %
CYPH100%
+2.95%
INKT - CYPH
42%
Loosely correlated
+0.58%
AXON - CYPH
40%
Loosely correlated
+0.10%
SABS - CYPH
36%
Loosely correlated
-0.29%
AMRN - CYPH
35%
Loosely correlated
-1.71%
ALLR - CYPH
30%
Poorly correlated
-2.40%
More

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then REVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
-0.29%
REVB - SABS
48%
Loosely correlated
+0.34%
INKT - SABS
47%
Loosely correlated
+0.58%
CYPH - SABS
46%
Loosely correlated
+2.95%
TECX - SABS
35%
Loosely correlated
+1.54%
BEAM - SABS
31%
Poorly correlated
-1.56%
More